<DOC>
	<DOC>NCT00707304</DOC>
	<brief_summary>The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens.</brief_summary>
	<brief_title>Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>Histologically or cytologically confirmed stage IIIB or IV NSCLC Failed at least 2 prior systemic anticancer regimens for advanced or metastatic NSCLC At least one target lesion that is unirradiated and measurable by RECIST Adequate hematologic, renal and hepatic function ECOG 0, 1, or 2 Able to understand and sign an Informed Consent Presence of brain metastases, unless the patient received brain irradiation, including adequate stereotactic radiosurgery, at least 4 weeks prior to randomization, and is stable, asymptomatic, and off steroids for at least 3 weeks prior to randomization Any gastrointestinal tract disease or other medical condition resulting in the inability to take oral medications History of other malignancies except: (i) adequately treated basal or squamous cell carcinoma of the skin; (ii) curatively treated, a) in situ carcinoma of the uterine cervix, b) prostate cancer, or c) superficial bladder cancer; or (iii) other curatively treated solid tumor with no evidence of disease for â‰¥ 5 years Uncontrolled ischemic heart disease, or uncontrolled symptomatic congestive heart failure Serious active infection Psychiatric illness/ social situations that would limit study compliance Other uncontrolled serious chronic disease or conditions that in the investigator's opinion could affect compliance or followup in the protocol Concurrent radiotherapy to any site or radiotherapy within 4 weeks prior to randomization or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response) Known HIV positive or on active antiretroviral therapy Known Hepatitis B surface antigen positive or hepatitis C positive Receipt of any investigational medication within 4 weeks prior to randomization Pregnant or lactating patients, or fertile female patients with a positive pregnancy test, or fertile female patients unwilling to use adequate contraception during treatment and 30 days after completion of treatment Sexually active male patients unwilling to practice contraception while participating on the study and up to 30 days after completion of treatment Legal incapacity or limited legal capacity, unless authorization is granted by a legal guardian</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Talactoferrin</keyword>
	<keyword>Dendritic Cell Recruiter and Activator</keyword>
	<keyword>Immunomodulatory agent</keyword>
</DOC>